Myelodysplastic Syndromes
This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukem...
保存先:
| フォーマット: | Online |
|---|---|
| 言語: | 英語 |
| 出版事項: |
IntechOpen
2021
|
| 主題: | |
| オンライン･アクセス: | ONIX_20210420_9789535125877_2261 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
| _version_ | 1869530030380417024 |
|---|---|
| collection | Directory of Open Access Books |
| description | This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML. |
| format | Online |
| id | doab-20.500.12854ir-66902 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | ojs |
| spelling | doab-20.500.12854ir-669022024-04-01T14:13:17Z Myelodysplastic Syndromes Fuchs, Ota Pathology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML. 2021-04-20T15:56:57Z 2021-04-20T15:56:57Z 2016 book ONIX_20210420_9789535125877_2261 9789535125877 9789535125860 9789535172963 https://directory.doabooks.org/handle/20.500.12854/66902 eng image/jpeg n/a https://www.intechopen.com/books https://mts.intechopen.com/storage/books/5276/authors_book/authors_book.pdf IntechOpen IntechOpen 10.5772/61879 10.5772/61879 78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6 9789535125877 9789535125860 9789535172963 IntechOpen 210 open access |
| spellingShingle | Pathology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology Myelodysplastic Syndromes |
| title | Myelodysplastic Syndromes |
| title_full | Myelodysplastic Syndromes |
| title_fullStr | Myelodysplastic Syndromes |
| title_full_unstemmed | Myelodysplastic Syndromes |
| title_short | Myelodysplastic Syndromes |
| title_sort | myelodysplastic syndromes |
| topic | Pathology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology |
| topic_facet | Pathology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology |
| url | ONIX_20210420_9789535125877_2261 |